Vir Biotechnology Inc. announced that it has granted Norgine Pharma UK Limited an exclusive commercial license for the combination of tobevibart and elebsiran, an investigational treatment for chronic hepatitis delta, in Europe, Australia, and New Zealand. Under the terms of the agreement, Vir Biotechnology will receive an initial reimbursement payment of EUR 55 million and is eligible for up to EUR 495 million in clinical, regulatory, and sales milestones, as well as tiered royalties on net sales in Norgine's licensed territory. Vir Biotechnology will retain commercialization rights for the products in the United States and other markets outside Greater China. The agreement also includes a global cost-sharing arrangement for ongoing clinical development, with Norgine contributing approximately 25% of future external costs related to the ECLIPSE registrational program. The transaction in certain jurisdictions is subject to regulatory approvals.